Gruss & Co’s CRISPR Therapeutics CRSP Stock Holding History

Gruss & Co’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,500	Closed	-$280K	–	34
2021 Q3	$280K	Buy	+2,500	New	+$314K	0.78%	24

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Gruss & Co's CRSP Position: Q4 2021 in Review

Gruss & Co sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 2,500 shares — an estimated $280K sold.

Gruss & Co first reported a position in CRSP in Q3 2021 and held it in 1 quarter. The position peaked at $280K in Q3 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

Gruss & Co reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
Gruss & Co sold 2,500 CRISPR Therapeutics shares in Q4 2021, an estimated $280K.
Gruss & Co first reported a position in CRISPR Therapeutics in Q3 2021 and held it in 1 quarter.
Gruss & Co's CRISPR Therapeutics position peaked at $280K in Q3 2021.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Gruss & Co's 13F filing for Q4 2021, filed 31 Jan 2022.